Table 1.
Actual Susceptibility Result |
||
---|---|---|
|
||
Penicillin | Oxacillin or Cefoxitin |
Inferred Susceptibility Result |
S | S | S to penicillins (penicillinase-labilea and stableb), β-lactam/β-lactamase inhibitor combinationsc, cephemsd, and carbapenemse |
| ||
R | S | R to penicillinase-labile penicillins |
S to penicillinase-stable penicillins, β-lactam/β-lactamase inhibitor combinations, antistaphylococcal cephems, and carbapenems | ||
| ||
R | R | R to penicillins, β-lactam/β-lactamase inhibitor combinations, cephems, and carbapenems except newer cephalosporins with anti-MRSA activity (when confirmed by standardized testing [eg, ceftaroline]) |
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; R, resistant; S, susceptible.
Penicillinase-labile penicillins: amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, penicillin, piperacillin, ticarcillin.
Penicillinase-stable penicillins: cloxacillin, dicloxacillin, flucloxacillin, methicillin, nafcillin oxacillin.
β-Lactam/β-lactamase inhibitor combinations: amoxicillin-clavulanic acid, ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid.
Antistaphylococcal cephems include the oral cephems (cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, loracarbef) and the parenteral cephems (cefamandole, cefazolin, cefepime, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefotetan, ceftizoxime, ceftriaxone, cefuroxime, cephalothin, ceftaroline moxalactam) for indications approved by the US Food and Drug Administration or other regulatory bodies in the country of use.
Carbapenems: doripenem, ertapenem, imipenem, meropenem.